GSTM1, GSTT1, GSTP1 and CYP1A1 genetic polymorphisms and susceptibility to esophageal cancer in a French population: Different pattern of squamous cell carcinoma and adenocarcinoma

Table 1 Primer sequences and length of PCR products

Gene	Primer sequence	Size of PCR product (bp)	Reference
GSTM1	5’-GAACTCCCTGAAAAGCTAAAGC-3’	219	Lin et al
	5’-GTTGGGCTCAAATATACGGTGG-3’		1998[24]
GSTT1	5’-TTCCTTACTGGTCCTCACATCTC-3’	459
	5’-TCACCGGATCATGGCCAGCA-3’
Albumin	5’-GCCCTCTGCTAACAAGTCCTAC-3’	350
	5’-GCCCTAAAAAGAAAATCCCCAATC-3’
GSTP1	5’-ACCCCAGGGCTCTATGGGAA-3’	176	Harries et al
	5’-TGAGGGCACAAGAAGCCCCT-3’		1997[16]
CYP1A1	5’-GGCTGAGCAATCTGACCCTA-3’	206	Cascorbi et al
	5’-TTCCACCCGTTGCAGCAGGATAGCC-3’		1996[8]

Table 2 Description of control and case populations

	Control n (%)	Case n (%)	SCC n (%)	ADC n (%)
Male	87 (0.67)	69 (0.87)	44 (0.85)	25 (0.93)
Female	43 (0.33)	10 (0.13)	8 (0.15)	2 (0.07)
Mean age (yr)	56 [19; 87]	62 [40; 85]	60 [40; 78]	66 [51; 85]
Tobacco duration12 (years of smoking)
Non-smokers	66 (0 .66)	6 (0.13)	2 (0.07)	4 (0.22)
1-19	13 (0.13)	2 (0.04)	0 (-)	2 (0.11)
+20	21 (0.21)	40 (0.83)	28 (0.93)	12 (0.67)
Alcohol consumption34 (g of ethanol per week)
0-228	11 (0.64)	13 (0.28)	4 (0.14)	9 (0.50)
228.5 - / + 470	6 (0.36)	35 (0.72)	26 (0.86)	9 (0.50)

¹Tobacco duration (year);

²Data were available for 77% of controls, 61% of cases, including 58% of SCC and 67% of ADC;

³Alcohol consumption (gram of ethanol per week);

⁴Data for alcohol consumption were available for only 13% of controls, 61% of cases, including 58% of SCC and 67% of ADC.

Table 3 Repartition of CYP1A1 genotypes among controls and cases

	n	CYP1A1*1A/*1A		CYP1A1*1A/*2C			OR1	95%CI
		n	(%)	n	(%)
Controls	107	101	(94)	6	(6)
Cases	70	61	(87)	9	(13)	All cases vs controls2	2.63	[0.84-8.28]
SCC	47	40	(85)	7	(15)	SCC vs controls3	3.03	[0.93-9.90]5
ADC	23	21	(91)	2	(9)	ADC vs controls4	2.06	[0.33-13.04]

¹Adjusted OR for age and sex;

²Comparison of CYP1A1*1A/*2C genotype repartition in controls vs all cases;

³Comparison of CYP1A1*1A/*2C genotype repartition in controls vs SCCs;

⁴Comparison of CYP1A1*1A/*2C genotype repartition in controls vs ADCs;

⁵P = 0.067.

Table 4 Repartition of GSTM1 genotypes among controls and cases

	n	GSTM1*2/*2			OR1	95%CI
		n	(%)
Controls	120	59	(49)
Cases	68	39	(57)	All cases vs controls2	1.43	[0.76-2.69]
SCC	43	27	(63)	SCC vs controls3	1.83	[0.88-3.83]5
ADC	25	12	(48)	ADC vs controls4	0.95	[0.38-2.41]

¹Adjusted OR for age and sex;

²Comparison of GSTM1*2/*2 genotype repartition in controls vs all cases;

³Comparison of GSTM1*2/*2 genotype repartition in controls vs SCCs;

⁴Com-parison of GSTM1*2/*2 genotype repartition in controls vs ADCs;

⁵P = 0.108.

Table 5 Repartition of GSTT1 genotypes among controls and cases

	n	GSTT1*2/*2			OR1	95%CI
		n	(%)
Controls	115	30	(26)
Cases	70	14	(20)	All cases vs controls2	1.78	[0.84-3.80]
SCC	44	13	(29)	SCC vs controls3	1.03	[0.46-2.27]
ADC	26	1	(4)	ADC vs controls4	13.31	[1.66-106.92]a

¹Adjusted OR for age and sex;

²Comparison of GSTT1*2/*2 genotype repartition in controls vs all cases;

³Comparison of GSTT1*2/*2 genotype repartition in controls vs SCCs;

⁴Comparison of GSTT1*2/*2 genotype repartition in controls vs ADCs;

^aP < 0.05.

Table 6 Repartition of GSTP1 genotypes among controls and cases

	n	GSTP1							OR12	95%CI
		Ile/Ile		Ile/Val		Val/Val
		n	(%)	n	(%)	n	(%)
Controls	124	59	(48)	56	(45)	9	(7)
Cases	70	31	(44)	33	(47)	6	(9)	All cases vs controls3	1.02	[0.55-1.89]
SCC	45	21	(47)	21	(47)	3	(6)	SCC vs controls4	0.95	[0.47-1.91]
ADC	25	10	(40)	12	(48)	3	(12)	ADC vs controls5	1.17	[0.46-2.97]

¹Adjusted OR for age and sex;

²Ile/Val and Val/Val genotypes were compared to Ile/Ile genotype;

³Comparison of GSTP1 Ile/ Val and Val/Val genotype repartition in controls versus all cases;

⁴Comparison of GSTP1 Ile/Val and Val/Val genotype repartition in controls vs SCCs;

⁵Comparison of GSTP1 Ile/Val and Val/Val genotype repartition in controls vs ADCs.